SHTDF (Sinopharm Group Co) Moat Score: 6/10 (As of Jun. 25, 2026)


SHTDF Sinopharm Group Co Ltd SHTDF
78 GF Score
Price $2.29
GF Value $2.78
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Moat Score?

Sinopharm Group Co SHTDF -2.67% 78 Moat Score is 6 as of Jun. 25, 2026. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 121 Medical Distribution companies, Sinopharm Group Co ranks better than 97.52% on this metric.

Sinopharm Group Co has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sinopharm Group Co has Narrow Moat: Sinopharm Group Co Ltd benefits from a strong distribution network and significant regulatory barriers in the pharmaceutical distribution industry. It has a strong narrow moat due to its scale and market leadership in China, but lacks the global dominance for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sinopharm Group Co might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Sinopharm Group Co  (OTCPK:SHTDF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sinopharm Group Co Moat Score Related Terms

SHTDF vs MCK, COR, CAH: Moat Score Comparison

For the Medical Distribution subindustry, Sinopharm Group Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co Moat Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Moat Score distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Moat Score falls into.


SHTDF
78GF Score
Sinopharm Group Co Ltd SHTDF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Sinopharm Group Co (SHTDF) has a Moat Score of 6 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sinopharm Group Co ranks #3 out of 121 companies in the Medical Distribution industry, placing it in the top 2.5%.
Is Sinopharm Group Co's Moat Score too high?
Sinopharm Group Co's current Moat Score is 6. Based on the distribution chart, Sinopharm Group Co ranks #3 out of 121 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Moat Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #3 out of 121 companies for Moat Score. This places Sinopharm Group Co in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Distribution company?
A good Moat Score depends on the Medical Distribution industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sinopharm Group Co's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.78, compared to a current price of $2.29 — trading 17.7% below its estimated fair value. The current Moat Score is 6. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Moat Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDF) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $2.29 is trading 17.7% below its estimated GF Value™ of $2.78. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDF:

  • Moat Score: 6
  • GF Value™: $2.78 vs. price of $2.29 (17.7% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score

Get the complete analysis for SHTDF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.29
Price
$2.78
GF Value